Here’s a closer look at last week’s top gainers.
The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) was down 0.59 percent over the last five trading days and ended the week at 3,146.06 points. The Index is up 13.46 percent year-to-date.
Last week, a tweet from the U.S. president sent pharma stocks down and the Canadian Parliament passed a Bill to prohibit discrimination based on genetic testing. The XBI is just above $70 and IBB is also just over $300. Fierce Biotech reported on Juno Therapeutics (NASDAQ: JUNO) decision to stop testing its CAR-T therapy after recent patient deaths. GEN reported on Tocagen, a gene therapy developer, seeking to raise $86 million through an IPO.
Here is a closer look at the top five NASDAQ gainers in the biotechnology and pharmaceuticals space:
- Aurinia Pharmaceuticals (NASDAQ:AUPH)
- Curis Inc. (NASDAQ:CRIS)
- Immunomedics (NASDAQ:IMMU)
- Atara Biotherapeutics (NASDAQ:ATRA)
- Adamis Pharmaceuticals (NASDAQ:ADMP)
Aurinia is a biopharmaceutical company focused on the global immunology market. Early last week the company released their financial results for 2016 and announced new clinical trials as the basis for a New Drug Application.
Aurinia Pharmaceuticals gained 76.72 percent over the five-day trading week and ended at $8.50 per share.
This biotechnology company is focused on developing and commercializing drug candidates to treat human cancers. The company released its financial results for 2016 last week. However, there has been no further recent news from the company to explain last week’s rise in share price.
Curis gained 24.37 percent over the five-day trading week and ended at $2.96 per share.
Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer. A deal that set between the company and Seattle Genetics (NASDAQ:SGEN) was put on hold last week by a Delaware judge who argued Immunomedics has a fight for management.
The company gained 23.11 percent over the five-day trading week and ended at $6.34 per share.
Atara is a company focused on helping patients treating with cancer by changing the disease progression. The company recently released its financial results for 2016. However, there has been no further recent news from the company to explain last week’s rise in share price.
Atara Biotherapeutics gained 22.45 percent over the five-day trading week and ended at $21 per share.
This company is a biopharmaceutical providing low-cost solutions with respiratory diseases and allergies. In January announced that the FDA has accepted for review the company’s NDA for its epinephrine pre-filled syringe. However, there has been no further recent news from the company to explain last week’s rise in share price.
Adamis Pharmaceuticals gained 21.68 percent over the five-day trading week and ended at $4.35 per share.
Don’t forget to follow @INN_LifeScience for real-time updates!
Data for 5 Top NASDAQ Stocks articles is retrieved each Friday after market close using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $10 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Related reading, previous gainers:
5 Top NASDAQ Biotech Stocks: Cerulean Pharma gained 118.42 percent
5 Top NASDAQ Biotech Stocks: Aurinia Pharmaceuticals gained 76.72 percent
5 Top NASDAQ Biotech Stocks: HTG Molecular Diagnostics Gains 128.46 Percent